Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
504-04-007 ISMRM Abstract

Amine-CEST MRI with Gadolinium Contrast Differentiates Tumor Progression from Pseudo-progression/ Radiation Necrosis

Primary: Preclinical Animal & in vitro MR - Biomarkers
Secondary: Preclinical Animal & in vitro MR - Biology, Models, Methods
504-04-007 · Cancer Imaging and Spectroscopy · Wednesday, 13 May, 4:00 PM–5:50 PM · Ballroom East
Keywords: CEST & MT CEST / APT / NOE CEST MRI Radiation therapy CEST MRI in vivo
Accepted
Blake A Benyard 1, Narayan Datt Soni1, Nishi Srivastava2, Anshuman Swain3, Junyoung Shin4, RAVI PRAKASH REDDY NANGA1,5, Nadir Yehya2, Yi Fan3, Ravinder Reddy1,5,6,7, Mohammad Haris3
1Department of Radiology, University of Pennsylvania, Philadelphia, United States of America
2Children's Hospital of Philadelphia, Philadelphia, United States of America
3University of Pennsylvania, Philadelphia, United States of America
4Radiation Oncology, University of Pennsylvania, Philadelphia, United States of America
5Center for Advanced Metabolic Imaging in Precision Medicine, Philadelphia, United States of America
6Center for Advanced Metabolic Imaging in Precision Medicine, Center for Advanced Metabolic Imaging in Precision Medicine, Philadelphia, United States of America
7Center for Advanced Metabolic Imaging in Precision Medicine, University of Pennsylvania, Philadelphia, United States of America
Presenting Author: Blake A Benyard

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Thust, S.C., van den Bent, M.J. and Smits, M. Pseudoprogression of brain tumors. J. Magn. Reson. Imaging, 2018; 48: 571-589.
2. Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019 Nov;16(4):655-670.
3. Reckamp KL Real-world pseudoprogression: an uncommon phenomenon. J Thorac Oncol. 2018;13:880–2.
4. Li Y, Ma Y, Wu Z, et al. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. Front Immunol. 2021; 12:790674.
5. Manning P, Daghighi S, Rajaratnam MK, et al. Differentiation of Progressive Disease From Pseudoprogression Using 3d Pcasl and Dsc Perfusion Mri in Patients With Glioblastoma. J Neurooncol. 2020; 147:681–90.
6. Xu Q, Liu Q, Ge H, et al. Tumor Recurrence Versus Treatment Effects in Glioma: A Comparative Study of Three Dimensional Pseudo-Continuous Arterial Spin Labeling and Dynamic Susceptibility Contrast Imaging. Med. 2017; 96: e9332.
7. Song YS, Choi SH, Park CK, et al. True Progression Versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis. Korean J Radiol. 2013; 14:662–72.
8. Chu HH, Choi SH, Ryoo I, et al. Differentiation of True Progression From Pseudoprogression in Glioblastoma Treated With Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-B-Value Diffusion-Weighted Imaging. Radiology. 2013; 269:831–40.
9. Cai K, Singh A, Poptani H, et al. CEST signal at 2ppm (CEST@2ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor. NMR Biomed. 2015;28(1):1-8.
10. Torrealdea, Francisco & Hearle, J & Evans, et al. APT-CEST post Gadolinium. Should it be avoided? Comparison of pre- & post- Gadolinium CEST on glioma at 3T. Intl. Soc. Mag. Reson. Med. 26 (2018).

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/504-04-007